This Month in Gastroenterology Laura Harrell, Eugene B. Chang  Gastroenterology  Volume 130, Issue 2, Pages 289-291 (February 2006) DOI: 10.1053/j.gastro.2006.01.013 Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 1 Percentage of patients in each adalimumab dose group and the placebo group achieving remission at weeks 1, 2, and 4 (*P = .001 vs placebo). Gastroenterology 2006 130, 289-291DOI: (10.1053/j.gastro.2006.01.013) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 2 Increased CHI3L1 expression in human IBD. A–F Immunohistochemical analysis of the expression of CHI3L1 is shown A objective, 20×; B–F objective, 40×). Colonic tissue obtained from normal individual (A and B), Crohn’s disease (C and D), and ulcerative colitis (E and F) patients were stained with rabbit anti-human CHI3L1 (A–C, E and F) or normal rabbit serum D. Gastroenterology 2006 130, 289-291DOI: (10.1053/j.gastro.2006.01.013) Copyright © 2006 American Gastroenterological Association Terms and Conditions

Figure 3 Dipeptidyl peptidase IV (DPPIV)-mutant F344 rat model to study liver repopulation by transplanted cells isolated from ED14 fetal rat liver. Isolated wild type cells are infused into the liver through the portal vein into DPPIV- mutant rats and their fate, proliferation, and morphologic appearance monitored by enzyme histochemistry or immunohistochemistry for DPPIV. Cells that have differentiated into hepatocytes are shown in the left inset and cells that have differentiated into cholangiocytes are shown in the right inset. Gastroenterology 2006 130, 289-291DOI: (10.1053/j.gastro.2006.01.013) Copyright © 2006 American Gastroenterological Association Terms and Conditions